title: High relapse rate seen at week 72 for patients treated with R1626 combination therapy.
authors.forename: Paul
authors.initials: P
authors.lastname: Pockros
authors.forename: David
authors.initials: D
authors.lastname: Nelson
authors.forename: Eliot
authors.initials: E
authors.lastname: Godofsky
authors.forename: Maribel
authors.initials: M
authors.lastname: Rodriguez-Torres
authors.forename: Gregory T
authors.initials: GT
authors.lastname: Everson
authors.forename: Michael W
authors.initials: MW
authors.lastname: Fried
authors.forename: Reem
authors.initials: R
authors.lastname: Ghalib
authors.forename: Stephen
authors.initials: S
authors.lastname: Harrison
authors.forename: Lisa
authors.initials: L
authors.lastname: Nyberg
authors.forename: Mitchell L
authors.initials: ML
authors.lastname: Shiffman
authors.forename: Anna
authors.initials: A
authors.lastname: Chan
authors.forename: George
authors.initials: G
authors.lastname: Hill
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000188:drug therapy* / Q000517:prevention & control*; D006801:Humans; D015994:Incidence; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D009705:Nucleosides / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011355:Prodrugs / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012008:Recurrence; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009705:Nucleosides; D011355:Prodrugs; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a; C530825:balapiravir